Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
664-02-013 ISMRM Abstract

In-vivo vs. in-vitro characterization of ferumoxytol sensitivity and relative T1 contrast at different field strengths

Primary: Contrast Mechanisms - Contrast Agents
Secondary: Preclinical Animal & in vitro MR - Large Animals, Nonhuman Primates
664-02-013 · Large Animals · Thursday, 14 May, 9:25 AM–10:20 AM · Digital Posters Row E
Keywords: Low-Field MRI Cardiovascular magnetic resonance Myocardial T1-mapping Ferumoxytol-enhanced imaging Relaxivity
Accepted
Hazar Benan Unal1,2, Shahriar Zeynali1,2,3, Eric Anttila4, Rohan Dharmakumar5, David C Gross 4, Behzad Sharif1
1Weldon School of Biomedical Engineering, Purdue University, West Lafayette, United States of America
2Laboratory for Translational Imaging for Microcirculation, Weldon School of Biomedical Engineering, Purdue University, West Lafayette, United States of America
3Department of Radiology & Imaging Sciences, Indiana University School of Medicine, Indianapolis, United States of America
4MED Institute, West Lafayette, United States of America
5Indiana University School of Medicine, Indianapolis, United States of America
Presenting Author: David C Gross

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Lehrman ED, Plotnik AN, Hope T, Saloner D. Ferumoxytol-enhanced MRI in the peripheral vasculature. Clin Radiol. 2019;74:37-50. doi: 10.1016/j.crad.2018.02.021 [doi]
2. Toth GB, Varallyay CG, Horvath A, Bashir MR, Choyke PL, Daldrup-Link HE, Dosa E, Finn JP, Gahramanov S, Harisinghani M, et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int. 2017;92:47-66. doi: 10.1016/j.kint.2016.12.037 [doi]
3. Bravo SM, Myers C, Bravo T, Elenberger C, Posniak R, Dattoli M. Ferumoxytol as a lymph node contrast agent in patients with metastatic prostate carcinoma. Pract Radiat Oncol. 2013;3:S11. doi: 10.1016/j.prro.2013.01.037 [doi]
4. Colbert CM, Thomas MA, Yan R, Radjenovic A, Finn JP, Hu P, Nguyen KL. Estimation of fractional myocardial blood volume and water exchange using ferumoxytol-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2021;53:1699-1709. doi: 10.1002/jmri.27494 [doi]
5. Colbert CM, Le AH, Shao J, Currier JW, Ajijola OA, Hu P, Nguyen KL. Ferumoxytol-enhanced magnetic resonance T1 reactivity for depiction of myocardial hypoperfusion. NMR Biomed. 2021;34:e4518. doi: 10.1002/nbm.4518 [doi]
6. Unal HB, Zeynali S, Anttila E, Roll J, Kreutz R, Frick K, Raman SV, Gross D, Dharmakumar R, Sharif B. Rapid Mapping of Stress/rest Myocardial T1 Reactivity with Brief Intracardiac Infusion of Adenosine Enabled by a Commercially Available Icmr Paradigm. Journal of Cardiovascular Magnetic Resonance. 2024;26. doi: 10.1016/j.jocmr.2024.100280 [doi]
7. Wells SA, Schubert T, Motosugi U, Sharma SD, Campo CA, Kinner S, Woo KM, Hernando D, Reeder SB. Pharmacokinetics of Ferumoxytol in the Abdomen and Pelvis: A Dosing Study with 1.5- and 3.0-T MRI Relaxometry. Radiology. 2020;294:108-116. doi: 10.1148/radiol.2019190489 [doi]
8. Stoumpos S, Hennessy M, Vesey AT, Radjenovic A, Kasthuri R, Kingsmore DB, Mark PB, Roditi G. Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease. Eur Radiol. 2019;29:3543-3552. doi: 10.1007/s00330-019-06137-4 [doi]
9. Oberdick SD, Jordanova KV, Lundstrom JT, Parigi G, Poorman ME, Zabow G, Keenan KE. Iron oxide nanoparticles as positive T(1) contrast agents for low-field magnetic resonance imaging at 64 mT. Sci Rep. 2023;13:11520. doi: 10.1038/s41598-023-38222-6 [doi]
10. Knobloch G, Colgan T, Wiens CN, Wang X, Schubert T, Hernando D, Sharma SD, Reeder SB. Relaxivity of Ferumoxytol at 1.5 T and 3.0 T. Invest Radiol. 2018;53:257-263. doi: 10.1097/RLI.0000000000000434 [doi]
11. Campbell-Washburn AE, Ramasawmy R, Restivo MC, Bhattacharya I, Basar B, Herzka DA, Hansen MS, Rogers T, Bandettini WP, McGuirt DR, et al. Opportunities in Interventional and Diagnostic Imaging by Using High-Performance Low-Field-Strength MRI. Radiology. 2019;293:384-393. doi: 10.1148/radiol.2019190452 [doi]
12. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52:141-146. doi: 10.1002/mrm.20110 [doi]
13. Hazlewood CF, Chang DC, Nichols BL, Woessner DE. Nuclear magnetic resonance transverse relaxation times of water protons in skeletal muscle. Biophys J. 1974;14:583-606. doi: 10.1016/S0006-3495(74)85937-0 [doi]
14. Donahue KM, Weisskoff RM, Chesler DA, Kwong KK, Bogdanov AA, Jr., Mandeville JB, Rosen BR. Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med. 1996;36:858-867. doi: 10.1002/mrm.1910360608 [doi]
15. Zeynali S*, Unal HB*, Anttila E, Gross D, Dharmakumar R, Sharif B. Comparison of T1 sensitivity to ferumoxytol at 0.55T versus 3T: a preclinical cardiac MRI study. Paper/Poster presented at: Proceedings of the ISMRM Annual Meeting; May 10-15, 2025; Honolulu,HI, USA. doi: https://doi.org/10.58530/2025/0408 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/664-02-013